One-Year Results of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy

Yamamoto, Akiko; Okada, Annabelle A.; Kano, Mariko; Koizumi, Hideki; Saito, Masaaki; Maruko, Ichiro; Sekiryu, Tetsuju; Iida, Tomohiro

doi:10.1016/j.ophtha.2015.05.024

Cited by 118 publications

(95 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Using a fixed 2-month injection interval in the maintenance phase after an induction phase of 3 monthly doses, we previously reported good efficacy of aflibercept for PCV [10] , including a higher percentage of eyes with complete resolution of polypoidal lesions on indocyanine green angiography compared to treatment with other anti-VEGF agents [21,22] . Aflibercept is reported to have a higher binding affinity for VEGF-A than bevacizumab and ranibizumab, as well as a longer intraocular half-life [9,23] .…”

Section: Discussionmentioning

confidence: 99%

“…Furthermore, since our study included a fairly high percentage of PCV patients, as is typical for Japan, our results are difficult to compare to other treat-and-extend regimen studies from the US and Europe. Finally, a separate cohort of patients who were treated using a fixed 2-monthly dosing regimen as recommended by the pharmaceutical company was evaluated in a separate study that was published [10] . After explaining the advantages and disadvantages of each regimen, patients were given the liberty to choose between a fixed-dosing and a treat-and-extend regimen, and we acknowledge that this may have introduced unintended bias in the results of the current study.…”

Section: Discussionmentioning

confidence: 99%

“…We previously reported 1-year results of a multicenter study examining the efficacy of bimonthly intravitreal aflibercept injections during the maintenance phase after 3 monthly loading doses in 90 treatment-naïve polypoidal choroidal vasculopathy (PCV) eyes [10] . Although our results were generally good, 7 eyes had worsening of intraretinal or subretinal fluid between the fixed bimonthly doses and were given rescue injections, while 28.9% of the eyes still had intraretinal or subretinal fluid as assessed by optical coherence tomography (OCT) at the end of 1 year.…”

mentioning

confidence: 99%

See 2 more Smart Citations

One-Year Outcomes of a Treat-and-Extend Regimen of Aflibercept for Exudative Age-Related Macular Degeneration

Yamamoto

Okada²,

Nakayama³

et al. 2017

Ophthalmologica

Self Cite

View full text Add to dashboard Cite

Purpose: The aim of this study was to investigate the 1-year outcomes of treat-and-extend aflibercept for exudative age-related macular degeneration (AMD) in Japan. Procedures: Clinical records of 67 patients (67 eyes) were reviewed. Monthly aflibercept was administered until resolution of exudation and maximal reduction of pigment epithelial detachment. Injection intervals were extended by 2-week units up to 12 weeks if no exudation was observed and shortened for recurrence. Results: Mean best-corrected visual acuity (logarithm of the minimum angle of resolution) improved from 0.29 to 0.14 at 12 months (p < 0.0001). Mean central retinal thickness decreased from 430 μm to 236 μm at 12 months (p < 0.0001). Fifty-nine eyes (88.0%) achieved a dry macula with a mean of 8.3 injections by study end. The injection interval was extended to 10 weeks in 44.8% and to 12 weeks in 17.9% of eyes. Conclusions: At 1 year, good outcomes were obtained using treat-and-extend aflibercept for exudative AMD in Japan.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

One-Year Outcomes of a Treat-and-Extend Regimen of Aflibercept for Exudative Age-Related Macular Degeneration

Yamamoto

Okada²,

Nakayama³

et al. 2017

Ophthalmologica

Self Cite

View full text Add to dashboard Cite

show abstract

“…Intravitreal aflibercept (IVA) injections can improve the visual acuity and macular morphology in eyes with polypoidal choroidal vasculopathy (PCV) 1. Earlier studies using enhanced depth imaging optical coherence tomography (EDI-OCT) showed that the central choroid was thicker in eyes with PCV, and the central choroidal thickness (CCT) was reduced after antivascular endothelial growth factor (anti-VEGF) therapy 2–4.…”

Section: Introductionmentioning

confidence: 99%

Changes of choroidal structure after intravitreal aflibercept therapy for polypoidal choroidal vasculopathy

et al. 2016

View full text Add to dashboard Cite

show abstract

“…In our study, 5 out of 12 (42%) patients dropped out for financial reasons. Since Oishi et al [7] and Yamamoto et al [12] reported no financial issues for dropout patients we speculate that the inability for patients to pay for the injections was the reason why our dropout proportion was higher. CRT in the bimonthly group fluctuated after the initial 3 injections as compared with the PRN group.…”

Section: Discussionmentioning

confidence: 69%

Comparison of pro re nata versus Bimonthly Injection of Intravitreal Aflibercept for Typical Neovascular Age-Related Macular Degeneration

Mori

Takada²,

Haruyama³

et al. 2017

Ophthalmologica

View full text Add to dashboard Cite

Purpose: The aim of this study was to clarify the 1-year outcomes of pro re nata (PRN) and bimonthly intravitreal injections of aflibercept (IVA) for typical neovascular age-related macular degeneration (tAMD) after the initial 3 monthly IVA. Methods: We conducted a prospective, interventional study. Fifty-eight treatment-naïve patients with tAMD were randomly assigned to the PRN (30 patients) or the bimonthly (28 patients) treatment group. Both groups initially received 3 monthly IVA. Visual acuity, central macular retinal thickness (CRT), and central choroidal thickness (CCT) were evaluated at 12 months. Subanalysis was performed to identify factors associated with the best-corrected visual acuity (BCVA). Results: BCVA was significantly improved only in the bimonthly group at 12 months. CRT and CCT were significantly decreased in both groups. Subanalysis showed that the only factor associated with BCVA improvement at 12 months was the existence of pigment epithelial detachment at baseline. Conclusions: BCVA showed significant improvement only in the bimonthly group but not in the PRN group at 12 months.

show abstract

One-Year Results of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy

Cited by 118 publications

References 42 publications

One-Year Outcomes of a Treat-and-Extend Regimen of Aflibercept for Exudative Age-Related Macular Degeneration

One-Year Outcomes of a Treat-and-Extend Regimen of Aflibercept for Exudative Age-Related Macular Degeneration

Changes of choroidal structure after intravitreal aflibercept therapy for polypoidal choroidal vasculopathy

Comparison of pro re nata versus Bimonthly Injection of Intravitreal Aflibercept for Typical Neovascular Age-Related Macular Degeneration

Contact Info

Product

Resources

About